Evidence map›Paper›PMID 27651329›Full record

ReviewDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2017

[Merkel cell carcinoma of the eyelid. An often unrecognized tumor entity : Clinical aspects and treatment strategies].

R Hoerster, M Schlaak, K R Koch, M Ortmann, C Mauch, L M Heindl

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  5. Personalized treatment concepts in extraocular cancer.Advances in ophthalmology practice and research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

R HoersterZentrum für Augenheilkunde, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland. robert.hoerster@uk-koeln.de.
M SchlaakKlinik für Dermatologie und Venerologie, Hauttumorzentrum im CIO Köln-Bonn, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
K R KochZentrum für Augenheilkunde, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
M OrtmannZentrum für Pathologie, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
C MauchKlinik für Dermatologie und Venerologie, Hauttumorzentrum im CIO Köln-Bonn, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.
L M HeindlZentrum für Augenheilkunde, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma of the eyelid is an aggressive, highly malignant tumor of the skin. Totaling approximately 0.5 % of all tumors of the eyelid, it constitutes a relatively small group of lid tumors. Nevertheless Merkel cell carcinoma is of significance to the ophthalmologist. Because of its clinical presentation it can be easily confused as a chalazion, a hordeolum or the lesser aggressive basal cell carcinoma. This often leads to delayed treatment. In this article we describe clinical aspects, which aim to help the ophthalmologist suspect Merkel cell carcinoma earlier. Additionally we outline a diagnostic and therapeutic workup taking into consideration the special anatomy of the eyelid.

Indexed as

BlepharoplastyCarcinoma, Merkel CellDiagnosis, DifferentialEvidence-Based MedicineEyelid NeoplasmsFalse Negative ReactionsHumansOphthalmoscopyTreatment OutcomeBasal cell carcinomaChalazionEpidemiologyExcisionNeoplasia

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.